ArticleEndocrine2026
Risk factors for immune checkpoint inhibitor-related thyroid dysfunction: a retrospective cohort study.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeImmune checkpoint inhibitors (ICIs) are widely used to treat various malignancies; however, the high incidence of immune-related adverse events, including thyroid dysfunction, is a major clinical concern. Thyroid dysfunction occurs frequently, affects patient health and quality of life, and can be life-threatening when severe, necessitating prompt identification and management. Herein, we aimed to identify pretreatment risk factors associated with ICI-induced thyroid dysfunction.
methodsMedical records of patients administered ICIs were retrospectively reviewed. Data on patient age, sex, and body weight; primary tumor type; ICI agent; programmed death-ligand 1 status; disease stage; line(s) of treatment; and laboratory parameters measured before treatment initiation were extracted. These characteristics were compared between patients who developed thyroid dysfunction and those who did not.
resultsAn elevated pretreatment eosinophil count was significantly associated with thyroid dysfunction following ICI therapy. In the multivariable logistic regression analysis, eosinophil count remained significantly associated with thyroid dysfunction after adjustment for lactate dehydrogenase (LDH; adjusted odds ratio per 0.1 × 10³/µL increase, 2.18; 95% confidence interval [CI], 1.56-3.04; P < 0.001). Receiver operating characteristic analysis yielded an area under the curve of 0.812 (95% CI, 0.722-0.902). The optimal cutoff value was 0.2 × 10³/µL, with a sensitivity of 81.0% and a specificity of 68.2%.
conclusionAn elevated pretreatment eosinophil count was associated with subsequent thyroid dysfunction following ICI therapy after adjustment for LDH. Further prospective studies incorporating thyroid autoantibody status are required to determine its clinical utility as a candidate marker.
Indexed as
Identifiers
42627575What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.